Egalet Corporation was a big mover last session, as its shares rose almost 7% on the day. The move came on the back of the company’s announcement of FDA Advisory Committees Recommend Approval of Abuse-Deterrent ARYMO™ ER (Morphine Sulfate). This led to far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up 60.9% in the past one-month time frame.

None of the estimates for this stock were revised over the past 30 days. The Zacks Consensus Estimate also remained unchanged over the same time frame. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Egalet currently carries a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

EGALET CORP Price

EGALET CORP Price | EGALET CORP Quote

A better-ranked stock in the med-drugs space is Corcept Therapeutics Incorporated (CORT Quick QuoteCORT - Free Report) , which sports a Zacks Rank #1 (Strong Buy).

Is EGLT going up? Or down? Predict to see what others think: Up or Down

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>